The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Clinical Trial Details
Geo Regions
![Category Image](/sites/default/files/2024-04/hematologic-malignancies-icon.png)
Hematological Malignancies
Non-Fucosylated CD70-directed Antibody
PF-08046040, SGN-CD70 is an investigational compound. Its safety and efficacy have not been established.
A Phase 1 Study of SEA-CD70 in Myeloid Malignancies
Phase 1
NCT04227847
Active enrolling
Locations
United States, Netherlands
Study design
Participant Group/Arm
EXPERIMENTAL: Part A
SEA-CD70 dose escalation cohort in relapsed/refractory (HMA-failure) MDS
Intervention/Treatment
DRUG: SEA-CD70
Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle
Participant Group/Arm
EXPERIMENTAL: Part B
SEA-CD70 expansion cohort in relapsed/refractory (HMA-failure) MDS
Intervention/Treatment
DRUG: SEA-CD70
Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle
Participant Group/Arm
EXPERIMENTAL: Part C
SEA-CD70 expansion cohort in relapsed/refractory AML
Intervention/Treatment
DRUG: SEA-CD70
Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle
Participant Group/Arm
EXPERIMENTAL: Part D
SEA-CD70 + azacitidine dose-finding/dose optimization cohorts in relapsed/refractory MDS or MDS/AML, and previously untreated higher-risk MDS or MDS/AML
Intervention/Treatment
DRUG: SEA-CD70
Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle
DRUG: azacitidine
75mg/m\^2 injected under the skin (SC; subcutaneous) or given into the vein (IV; intravenously) on Days 1 through 7 of each treatment cycle.
Participant Group/Arm
EXPERIMENTAL: Part E
SEA-CD70 + azacitidine expansion cohort in previously untreated higher-risk MDS or MDS/AML
Intervention/Treatment
DRUG: SEA-CD70
Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle
DRUG: azacitidine
75mg/m\^2 injected under the skin (SC; subcutaneous) or given into the vein (IV; intravenously) on Days 1 through 7 of each treatment cycle.
Participant Group/Arm
EXPERIMENTAL: Part F
SEA-CD70 + azacitidine expansion cohort in relapsed/refractory MDS or MDS/AML
Intervention/Treatment
DRUG: SEA-CD70
Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle
DRUG: azacitidine
75mg/m\^2 injected under the skin (SC; subcutaneous) or given into the vein (IV; intravenously) on Days 1 through 7 of each treatment cycle.
Key eligibility criteria
Inclusion criteria
Part A Inclusion Criteria
- Participants with cytologically/histologically confirmed MDS according to the 2016 World Health Organization (WHO) classification with the following:
- Measurable disease per WHO MDS with excess blasts criteria as defined either:
- 5%-9% blasts in the bone marrow or 2%-4% blasts in the peripheral blood or
- 10%-19% blasts in the bone marrow or 5%-19% blasts in the peripheral blood
- MDS that is relapsed or refractory and must not have other therapeutic options known to provide clinical benefit in MDS available.
- Treatment failure after prior hypomethylating agent (HMA) therapy for MDS, defined as one of the following:
- Progression (per 2006 International Working Group [IWG] criteria) at any time after initiation of HMA therapy.
- Lack of response (failure to achieve complete remission [CR], partial response [PR], or hematologic improvement [HI] per 2006 IWG criteria) after at least 6 cycles of azacitidine (or equivalent HMA) or 4 cycles of decitabine (or equivalent HMA).
- Relapse after achievement of CR, PR, or HI (per 2006 IWG criteria).
- Intolerance of HMA (Grade 3 or higher non-hematologic toxicity leading to treatment discontinuation).
- Participants with isolated 5q-/5q- syndrome must have progressed, failed, relapsed, or not tolerated lenalidomide in addition to HMA.
- Measurable disease per WHO MDS with excess blasts criteria as defined either:
- Must be off HMA therapy ≥ 2 weeks and must be off any other treatments for MDS for ≥ 4 weeks prior to first dose of SEA-CD70; growth factors and transfusions are allowed before and during the study as clinically indicated
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Part B Inclusion Criteria
- Participants with cytologically/histologically confirmed MDS according to the WHO classification with the following:
- Measurable disease per WHO MDS with excess blasts (MDS-EB) criteria as defined either:
- 5%-9% blasts in the bone marrow or 2%-4% blasts in the peripheral blood, or
- 10%-19% blasts in the bone marrow or 5%-19% blasts in the peripheral blood
- MDS that is relapsed or refractory and must not have other therapeutic options known to provide clinical benefit in MDS available.
- Treatment failure after prior HMA therapy for MDS defined as one of the following:
- Progression (per 2006 IWG criteria) at any time after initiation of HMA therapy.
- Lack of response (failure to achieve CR, PR, or HI per 2006 IWG criteria) after at least 6 cycles of azacitidine or 4 cycles of decitabine.
- Relapse after achievement of CR, PR, or HI (per 2006 IWG criteria).
- Intolerance of HMA (Grade 3 or higher non-hematologic toxicity leading to treatment discontinuation).
- Participants with isolated 5q-/5q- syndrome must have progressed, failed, relapsed, or not tolerated lenalidomide in addition to HMA.
- Measurable disease per WHO MDS with excess blasts (MDS-EB) criteria as defined either:
- Must be off HMA therapy ≥ 2 weeks and must be off any other systemic treatments for MDS for ≥ 4 weeks prior to first dose of SEA-CD70; growth factors and transfusions are allowed before and during the study as clinically indicated.
- ECOG Performance Status of 0-2
Part C Inclusion Criteria
- Participants with relapsed or refractory AML according to International Consensus Classification (ICC) 2022 (except for acute promyelocytic leukemia [APL]):
- Who have received either 2 or 3 previous regimens to treat active disease. Post-remission treatments, intrathecal chemotherapy, and radiotherapy are not considered previous regimens.
- Who have received 1 previous regimen to treat active disease and have at least one of the following:
- Age > 60 and ≤75 years.
- Primary resistant AML (defined as failure to achieve CR after 1-2 courses of induction therapy)
- First CR duration <6 months
- Adverse-risk per European Leukemia Network genetic risk stratification
- Secondary AML (prior history of MDS or therapy-related)
- Age 18-75 years
- ECOG performance status of 0-2
Parts D and F Inclusion Criteria
- Participants with diagnosis of MDS or MDS/AML according to ICC 2022 criteria
- Disease which has relapsed, failed to respond after minimum of 6 cycles, or progressed following an HMA in the immediately preceding line of therapy.
- Eligible for continued therapy with azacitidine
- Must be off any other systemic treatment for AML/MDS. Must be off HMA therapy ≥ (greater than or equal to) 2 weeks and any other systemic treatments for MDS for ≥ (greater than or equal to) 4 weeks prior to first dose of SEA-CD70
- ECOG Performance Status 0-2
Parts D and E Inclusion Criteria
- Participants with diagnosis of MDS or MDS/AML according to ICC 2022 criteria, previously untreated.
- Participants with MDS/AML should not have AML-defining cytogenetics.
- Participants with higher-risk (Moderate High, High, or Very High) per Molecular International Prognostic Scoring System (IPSS-M) MDS and MDS/AML
- ECOG Performance Status 0-2
Exclusion criteria
Exclusion Criteria (All Parts)
- History of another malignancy within 3 years before the first dose of study drug or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.
- Previous exposure to CD70-targeted agents
- Prior allogeneic hematopoietic stem cell transplant, for any condition
- Central nervous system leukemia based on imaging or documented positive cytology in cerebral spinal fluid
- History of clinically significant sickle cell anemia, autoimmune hemolytic anemia, or idiopathic thrombocytopenic purpura
- Parts D and F only: Prior oral HMA or oral HMA-combinations
Key dates
Study start date
- August 2020
Estimated primary completion date
- November 2026
Key endpoints
Primary Outcome Measures
Outcome Measure
Number of participants with adverse events (AEs)
Measure Description
Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.
Time Frame
Through 30-37 days following last dose of SEA-CD70; up to approximately 2 years
Outcome Measure
Number of participants with laboratory abnormalities
Measure Description
To be summarized using descriptive statistics.
Time Frame
Through 30-37 days following last dose of SEA-CD70; up to approximately 2 years
Outcome Measure
Number of participants with a dose-limiting toxicity (DLT) at each dose level (Parts A and D only)
Measure Description
To be summarized using descriptive statistics.
Time Frame
Though end of DLT evaluation period; up to approximately 4 weeks
Secondary Outcome Measures:
Outcome Measure
AUC - Area under the plasma concentration-time curve
Measure Description
To be summarized using descriptive statistics.
Time Frame
Through 30-37 days following last dose of SEA-CD70; up to approximately 2 years
Outcome Measure
Tmax - Time to maximum concentration attained
Measure Description
To be summarized using descriptive statistics.
Time Frame
Through 30-37 days following last dose of SEA-CD70; up to approximately 2 years
Outcome Measure
Cmax - Maximum observed plasma concentration
Measure Description
To be summarized using descriptive statistics.
Time Frame
Through 30-37 days following last dose of SEA-CD70; up to approximately 2 years
Outcome Measure
Ctrough - Minimum plasma concentration per dosing interval
Measure Description
To be summarized using descriptive statistics.
Time Frame
Through 30-37 days following last dose of SEA-CD70; up to approximately 2 years
Outcome Measure
T1/2 - Terminal elimination half-life
Measure Description
To be summarized using descriptive statistics.
Time Frame
Through 30-37 days following last dose of SEA-CD70; up to approximately 2 years
Outcome Measure
Incidence of antidrug antibodies (ADA)
Measure Description
To be summarized using descriptive statistics.
Time Frame
Through 30-37 days following last dose of SEA-CD70; up to approximately 2 years
Outcome Measure
Complete remission (CR) Rate
Measure Description
Proportion of participants with AML or MDS who achieve CR
Time Frame
Up to approximately 4 years
Outcome Measure
Complete remission with incomplete blood count recovery (CRi) rate
Measure Description
Proportion of participants with AML who achieve CRi
Time Frame
Up to approximately 4 years
Outcome Measure
Complete remission with partial hematologic recovery (CRh) rate
Measure Description
Proportion of participants with AML or MDS who achieve CRh
Time Frame
Up to approximately 4 years
Outcome Measure
Hematologic response (HI) rate
Measure Description
Proportion of MDS participants with HI
Time Frame
Up to approximately 4 years
Outcome Measure
Overall response rate (ORR)
Measure Description
For AML, the proportion of participants who achieve a best response of CR, CRi, CRh, or partial response (PR). For MDS, the proportion of participants who achieve a best response of CR, CRh, or PR.
Time Frame
Up to approximately 4 years
Outcome Measure
Blast clearance rate for participants with MDS
Measure Description
Proportion of participants with MDS who achieve a best response of CR, CRh, or Marrow CR
Time Frame
Up to approximately 4 years
Outcome Measure
Duration of remission (DOR)
Measure Description
For AML, the time from first CR, CRi, CRh, or PR to the first documentation of disease progression or death due to any cause. For MDS, the time from first documentation of PR, CR, or CRh to the first documentation of disease progression or death due to any cause.
Time Frame
Up to approximately 4 years
Outcome Measure
Overall survival (OS)
Measure Description
Time from start of study treatment to the date of death due to any cause
Time Frame
Up to approximately 4 years
Outcome Measure
Event-free survival (EFS)
Measure Description
Time from first dose to the first documentation of progression, failure to achieve remission within the first 6 cycles, disease relapse, or death due to any cause, whichever comes first.
Time Frame
Up to approximately 4 years
Outcome Measure
MRD-negative ORR
Measure Description
Proportion of participants with AML or MDS who achieve objective response and MRD-negative status
Time Frame
Up to approximately 4 years
Outcome Measure
Time to response (TTR)
Measure Description
Time from start of study treatment to the first documentation of objective response
Time Frame
Up to approximately 4 years
Outcome Measure
Rate of conversion to transfusion independence (TI)
Measure Description
Proportion of participants who convert from transfusion dependence at baseline to TI post-baseline
Time Frame
Up to approximately 4 years
Outcome Measure
Rate of TI maintenance
Measure Description
Proportion of participants who were TI at baseline and maintain TI post-baseline
Time Frame
Up to approximately 4 years
Number of participants
140
Collaborators and investigators
Sponsor: Seagen Inc.
Collaborator: None